Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Boudouris

Neurology Farmington Hills, MI Doctor of Osteopathy

NPI 1205806577 CMS profile 54799

28595 Orchard Lake Rd, Suite 200, Farmington Hills, MI 48334

Open in the dashboard

General payments

$152,048

379 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Boudouris of Farmington Hills, MI is reported in the CMS Open Payments database as having received $152,048 across 379 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18 1
2024 General $547 37
2023 General $7,218 78
2022 General $44,411 70
2021 General $27,371 27
2020 General $26,583 41
2019 General $45,900 125

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Boudouris
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to William Boudouris were reported at $18. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year William Boudouris Neurology median Middle half National median
2019 $45,900 $474 $118–$2,177 $163
2020 $26,583 $367 $82–$2,309 $114
2021 $27,371 $438 $104–$2,547 $132
2022 $44,411 $442 $103–$2,388 $149
2023 $7,218 $464 $119–$2,312 $160
2024 $547 $468 $119–$2,323 $164
2025 $18 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $43,371 58 payments
  2. Genzyme Corporation $41,041 54 payments
  3. E.R. Squibb & Sons, L.L.C. $32,751 22 payments
  4. Celgene Corporation $17,835 29 payments
  5. Genentech USA, Inc. $14,709 35 payments
  6. AbbVie, Inc. $620 55 payments
  7. Novartis Pharmaceuticals Corporation $272 17 payments
  8. Avanir Pharmaceuticals, Inc. $184 21 payments
  9. Amgen Inc. $177 9 payments
  10. EMD Serono, Inc. $177 12 payments
  11. Other $912 67 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $122,352 56 payments
  2. Consulting Fee $20,828 8 payments
  3. Food and Beverage $6,547 298 payments
  4. Travel and Lodging $2,321 17 payments
Products named General payments · program years 2019–2025
  1. ZEPOSIA $49,378 49 payments
  2. VUMERITY $26,270 25 payments
  3. AUBAGIO Multiple Sclerosis $24,918 32 payments
  4. OCREVUS $14,709 35 payments
  5. TYSABRI $13,573 33 payments
  6. TECFIDERA $7,036 23 payments
  7. LEMTRADA $6,945 14 payments
  8. AUBAGIO Neurology $5,900 5 payments
  9. UBRELVY $562 46 payments
  10. QULIPTA $289 29 payments
  11. Other $1,981 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

2,849

Median for Neurology: 833

Drug cost

$510,575

Median for Neurology: $202,670

Branded share of claims

26.2%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vumerity Diroximel Fumarate Brand 14 $118,088
Copaxone Glatiramer Acetate Brand 16 $90,151
Teriflunomide Generic 21 $79,161
Nurtec Odt Rimegepant Sulfate Brand 24 $29,303
Lamictal Lamotrigine Brand 26 $24,745
Nuedexta Dextromethorphan Hbr/Quinidine Brand 13 $19,302
Emgality Pen Galcanezumab-Gnlm Brand 25 $19,141
Ubrelvy Ubrogepant Brand 17 $16,005
Dalfampridine Er Dalfampridine Brand 30 $14,616
Memantine Hcl Generic 338 $11,365

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$215,185

Of which drugs: $94,087

Medicare patients

685

Average age 73

Services billed

5,687

385 women, 300 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Diabetes 38%
Ischemic heart disease 36%
Depression 34%
Chronic kidney disease 32%
Alzheimer's or dementia 28%
Heart failure 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $153
$153 17 —
QULIPTA
  • AbbVie, Inc. $103
$103 — —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $81
$81 — —
APTIOM
  • Sumitomo Pharma America, Inc. $45
$45 — —
KEVEYIS
  • Xeris Pharmaceuticals, Inc. $39
$39 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

379 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record